GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis

Oncogene

Volumn 33, Issue 24, 2014, Pages 3195-3204

  Kalakonda, S ^a   Nallar, S C ^a   Lindner, D J ^b   Sun, P ^a   Lorenz, R R ^c   Lamarre, E ^c   Reddy, S P ^d   Kalvakolanu, D V ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

cytokines; cytoskeleton; metastasis; tumor suppression; tyrosine kinases

Indexed keywords

GRIM 19 PROTEIN; PROTEIN KINASE P60; STAT3 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL SHAPE; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; LYMPH NODE METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STRESS FIBER; UPREGULATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; MOUTH NEOPLASMS; MUTATION; NADH, NADPH OXIDOREDUCTASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEIN PP60(V-SRC); PHOSPHORYLATION; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902456919     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.271     Document Type: Article

References (47)

1. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004; 117: 989-998.
2. Superti-Furga G, Fumagalli S, Koegl M, Courtneidge SA, Draetta G. Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J 1993; 12: 2625-2634.
3. Hofmann ER, Boyanapalli M, Lindner DJ, Weihua X, Hassel BA, Jagus R et al. Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol 1998; 18: 6493-6504.
4. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 2000; 275: 33416-33426.
5. Zhang J, Yang J, Roy SK, Tininini S, Hu J, Bromberg JF et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 2003; 100: 9342-9347.
6. Lufei C, Ma J, Huang G, Zhang T, Novotny-Diermayr V, Ong CT et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003; 22: 1325-1335.
7. Stark GR, Darnell Jr JE. The JAK-STAT pathway at twenty. Immunity 2012; 36: 503-514.
8. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-83.
9. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553-2558.
10. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
11. Kalakonda S, Nallar SC, Gong P, Lindner DJ, Goldblum SE, Reddy SP et al. Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels. Am J Pathol 2007; 171: 1352-1368.
12. Sun P, Nallar SC, Kalakonda S, Lindner DJ, Martin SS, Kalvakolanu DV. GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring. Oncogene 2009; 28: 1339-1347.
13. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43: 969-980.
14. Oneyama C, Hikita T, Enya K, Dobenecker MW, Saito K, Nada S et al. The lipid raftanchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 2008; 30: 426-436.
15. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009; 15: 6852-6861.
16. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78.
17. Sabe H, Hata A, Okada M, Nakagawa H, Hanafusa H. Analysis of the binding of the Src homolog. 2 domain of Csk to tyrosine-phosphorylated proteins in the suppression and mitotic activation of c-Src. Proc Natl Acad Sci USA 1994; 91: 3984-3988.
18. Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y et al. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 1993; 73: 1125-1135.
19. Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006; 25: 7138-7147.
20. Liu YB, Shen WG, Ge H, Gai XD, Lu LL, Zhao XJ. [Expressions of survivin and GRIM-19 in prostate cancer]. Zhonghua nan ke xue 2011; 17: 21-26.
21. Zhou Y, Li M, Wei Y, Feng D, Peng C, Weng H et al. Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res 2009; 29: 695-703.
22. Zhou AM, Zhao JJ, Ye J, Xiao WH, Kalvakolanu DV, Liu RY. Expression and clinical significance of GRIM-19 in non-small cell lung cancer. Ai Zheng 2009; 28: 431-435.
23. Gong LB, Luo XL, Liu SY, Tao DD, Gong JP, Hu JB. Correlations of GRIM-19 and its target gene product STAT3 to malignancy of human colorectal carcinoma. Ai Zheng 2007; 26: 683-687.
24. Zhang Y, Hao H, Zhao S, Liu Q, Yuan Q, Ni S et al. Downregulation of GRIM-19 promotes growth and migration of human glioma cells. Cancer Sci 2011; 102: 1991-1999.
25. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
26. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 2011; 12: 413-426.
27. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001; 20: 6418-6434.
28. Buday L, Downward J. Roles of cortactin in tumor pathogenesis. Biochim Biophys Acta 2007; 1775: 263-273.
29. Li X, Zheng H, Hara T, Takahashi H, Masuda S, Wang Z et al. Aberrant expression of cortactin and fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Int J Oncol 2008; 33: 69-79.
30. Patel AS, Schechter GL, Wasilenko WJ, Somers KD. Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 1998; 16: 3227-3232.
31. Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M et al. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001; 61: 6906-6911.
32. Yamada S, Yanamoto S, Kawasaki G, Mizuno A, Nemoto TK. Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma. Pathol Oncol Res 2010; 16: 523-531.
33. Theocharis S, Klijanienko J, Giaginis C, Alexandrou P, Patsouris E, Sastre-Garau X. FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Cancer Res Clin Oncol 2012; 138: 1369-1377.
34. van Oijen MG, Rijksen G, ten Broek FW, Slootweg PJ. Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J Oral Pathol Med 1998; 27: 147-152.
35. Chen JY, Hung CC, Huang KL, Chen YT, Liu SY, Chiang WF et al. Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. Neoplasia 2008; 10: 1393-1401.
36. Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14: 4284-4291.
37. Matsouka PT, Flier JS. Relationship between c-src tyrosine kinase activity and the control of glucose transporter gene expression. Mol Endocrinol 1989; 3: 1845-1851.
38. White MK, Rall TB, Weber MJ. Differential regulation of glucose transporter isoforms by the src oncogene in chicken embryo fibroblasts. Mol Cell Biol 1991; 11: 4448-4454.
39. Valle Casuso JC, Gonzalez-Sanchez A, Medina JM, Tabernero A. HIF-1 and c-Src mediate increased glucose uptake induced by endothelin-1 and connexin43 in astrocytes. PLoS One 2012; 7: e32448.
40. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-337.
41. Jiang LQ, Feng X, Zhou W, Knyazev PG, Ullrich A, Chen Z. Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation. Oncogene 2006; 25: 5495-5506.
42. Fearnley IM, Carroll J, Shannon RJ, Runswick MJ, Walker JE, Hirst J. GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH:ubiquinone oxidoreductase (complex I). J Biol Chem 2001; 276: 38345-38348.
43. Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K et al. GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 2004; 24: 8447-8456.
44. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012; 48: 158-167.
45. Giannoni E, Taddei ML, Chiarugi P. Src redox regulation: again in the front line. Free Radic Biol Med 2010; 49: 516-527.
46. Suzuki K, Oneyama C, Kimura H, Tajima S, Okada M. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway. J Biol Chem 2011; 286: 15698-15706.
47. Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 1997; 3: 931-937.